Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.
To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.
Join us as we embark on an exciting journey in transforming the treatment landscape of acute myeloid leukemia (AML). We are searching for a dynamic and seasoned Associate Director/Director of Marketing to play a pivotal role in the development and implementation of comprehensive marketing strategies for our first commercial launch as an organization.
Reporting directly to the Senior Director of Brand Strategy and Marketing, you will be instrumental in crafting and executing integrated marketing plans to drive disease education, brand awareness and early adoption of our lead asset (ziftomenib). Working closely with cross-functional teams, your expertise in hematology/oncology, strategic thinking, and track record of successful marketing initiatives will be crucial in shaping, executing, and optimizing personalized omnichannel disease education and promotional campaigns targeted towards healthcare professionals (HCP), patients, caregivers and other relevant stakeholders.
- Campaign Development: Support the conceptualization and lead the implementation of integrated marketing campaigns, utilizing traditional and digital channels to effectively reach target audiences.
- Strategic Planning: Collaborate on the development and execution of strategic marketing plans aligned with our overall business objectives, aligned to the brand positioning and strategy for our lead asset (ziftomenib).
- Market Analysis: Utilize market research insights to uncover opportunities, identify trends, and assess competitive landscapes within the AML sector. Implement data-driven media and channel activation campaigns to optimize brand campaigns and performance.
- Messaging: Contribute to the creation of compelling and differentiated messaging tailored for key stakeholders (HCP and Patients), ensuring consistent and high-impact communication across all channels.
- Cross-functional Collaboration: Works closely with I&A, Medical Affairs, Sales, Legal, and Regulatory to ensure alignment and integration of marketing strategies and communications.
- KOL Engagement: Foster meaningful relationships with National, Regional and Local opinion leaders in hematology/oncology to create peer-to-peer exchange to build brand influencers and advocates.
- Budget Management: Contribute to the effective management of the marketing budget, optimizing resources to achieve maximum impact and return on investment.
- Performance Measurement: Support establishing and monitoring of key performance indicators (KPIs) to evaluate the success of marketing initiatives and adjust strategies accordingly.
- Bachelor’s degree in relevant field, advanced degree preferred.
- Minimum of 7 years of experience in marketing in the oncology or hematology space.
- Proven track record of developing and implementing fully integrated marketing strategies. Must have the ability to effectively collaborate with, motivate and influence various levels/grades within the organization and outside of the organization.
- Strong understanding of external stakeholder environment.
- Knowledge of marketing, strategic and long-range planning, training, and market access
- Excellent communication and interpersonal skills, with the ability to collaborate effectively with internal and external stakeholders.
- Demonstrated ability to lead and inspire cross-functional teams.
- Passion for improving the lives of patients and caregivers affected by oncology and hematology conditions. Ability to travel up to 15% of the time; domestic and limited international
- We work as one for patients
- We are goal-focused and deliver with excellence
- We are science-driven courageous innovators
- We strive to bring out the best in each other and ourselves
- Career advancement/ development opportunities
- Competitive comp package
- Bonus
- 401K + Employer contributions
- Generous stock options
- ESPP Plan
- 20 days of PTO to start
- 18 Holidays (Including Summer & Winter Break)
- Generous Benefits Package with a variety of plans available with a substantial employer match
- Paid Paternity/Maternity Leave
- In-Office Catered lunches
- Home Office Setup
- Lifestyle Spending Stipend
- Commuter Stipend (Boston Office)
- Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!
Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
What We Do
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Our pipeline includes tipifarnib, a farnesyl transferase inhibitor, currently in a registration-directed clinical trial and KO-539, a menin-MLL inhibitor, currently in a Phase 1/2A clinical trial.
For additional information, please visit our website at www.kuraoncology.com.
